Hepion Pharmaceuticals, Inc. announced positive topline results from its recently completed Phase II ALTITUDE-NASH clinical trial by demonstrating improved physiologic liver function and was well tolerated after four months of treatment in subjects with stage 3 or greater fibrosis based on the AGILE 3+ criteria.
[Hepion Pharamceutricals]